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Muscle loss is a serious complication in patients with diabetes mellitus (DM) and chronic kidney disease 
(CKD). However, studies on a long-term change in muscle mass presence or absence of DM and CKD are 
scarce. We included 6247 middle-aged adults from the Korean Genome and Epidemiology Study (KoGES) 
between 2001 and 2016. Bioimpedance analysis (BIA) was performed biennially. Patients were classified into 
four groups according to the presence or absence of DM and CKD. The primary outcome was muscle 
depletion, which was defined as a decline in fat-free mass index (FFMI) below the 10th percentile of all 
subjects. The secondary outcomes included the occurrence of cachexia, all-cause mortality, and the slopes of 
changes in fat-free mass and weight. During 73,059 person-years of follow-up, muscle depletion and cachexia 
occurred in 460 (7.4%) and 210 (3.4%), respectively. In the multivariable cause-specific hazards model, the 
risk of muscle depletion was significantly higher in subjects with DM alone than in those without DM and 
CKD (HR, 1.37; 95% CI, 1.04–1.80) and was strongly pronounced in subjects with both conditions (HR, 3.38; 
95% CI, 1.30–8.75). The secondary outcome analysis showed consistent results. The annual decline rates in 
FFMI, fat mass, and body mass index (BMI) were the steepest in subjects with DM and CKD among the four 
groups. DM and CKD are synergically associated with muscle loss over time. In addition, the mortality risk is 
higher in individuals with muscle loss. 
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INTRODUCTION 
 
Skeletal muscle is the primary reservoir of proteins in 
the body and thus supplies amino acids for energy 
production by various organs [1]. It is maintained by 
multiple pathways regulating cell and protein turnover 
and orchestrates metabolic homeostasis [2]. Muscle 
mass and strength decline with age. However, muscle 
loss is often excessive in critical conditions, such as 
cancer, sepsis, and burn injury [3–5]. In these 
conditions, proteolytic systems for protein degradation 
are activated, while protein synthesis decreases, thereby 
resulting in muscle fiber shrinkage [6]. Such catabolic 
processes can also occur in chronic illnesses, such as 
heart failure, diabetes mellitus (DM), and chronic 
kidney disease (CKD) [7–10]. A growing body of 
literature has demonstrated that chronic and gradual loss 
of muscle mass, which is known as “sarcopenia,” is 
more prominent in patients with DM than in those 
without DM [10]. Moreover, a number of studies have 
shown that muscle wasting is a serious complication 
and common in patients with CKD, particularly in those 
who receiving dialysis treatment [11]. More 
importantly, decreased muscle mass is associated with 
many comorbidities and poor quality of life, leading to 
increased mortality risk [12, 13]. 
 
Extreme muscle wasting often results in weight loss. 
Such a condition is generally referred to as cachexia, 
which is a complex metabolic syndrome that is associated 
with an underlying disease and characterized by muscle 
loss with or without fat mass loss [14]. Moreover, it is a 
serious condition that is not entirely reversed with 
nutritional supplementation [15]. Although the diagnostic 
criteria for cachexia have not yet been established, the 
most prominent characteristic of cachexia is weight loss 
[14, 16]. In advanced stages of chronic diseases [17, 18], 
cachexia prevalence is high, reaching 80% in patients 
with terminal cancer [19]. Thus, cachexia greatly 
contributes to increased mortality rates [20]. 
 
As previously mentioned, the clinical importance of 
muscle loss and cachexia has been highlighted not only 
in patients with critical illnesses but also in those with 
chronic diseases. DM and CKD are two of the 
conditions that can promote muscle wasting. Thus, 
close monitoring of muscle mass in patients with these 
conditions is crucial to prevent further muscle loss and 
sarcopenia-related complications. However, most 
studies to date have analyzed the association of baseline 
measurement of muscle mass with clinical outcomes, 
whereas relevant longitudinal studies with close 
monitoring of muscle mass are lacking. 
 
Hence, in this study, we aimed to examine the long-
term longitudinal association of DM and CKD with the 
development of muscle depletion, cachexia, and 
mortality in Korean adults from the Korean Genome 
and Epidemiology Study (KoGES). Using the body 
composition data assessed at every follow-up visit, we 
also compared the slopes of changes in muscle mass 
and body weight among four groups of subjects, which 
were identified according to the presence or absence of 






The study flow and baseline characteristics of the 
subjects are shown in Figure 1, Table 1 and 
Supplementary Table 1. The mean age of the subjects 
was 51.2 ± 8.6 years, and 48.1% were male. The average 
estimated glomerular filtration rate (eGFR) was 91.2 ± 
14.1 mL/min/1.73 m2. Systolic blood pressure (SBP) and 
BMI were significantly higher in subjects with DM than 
in those without DM. In addition, subjects with DM 
were more likely to have cardiovascular comorbidities, 
such as hypertension, coronary artery disease, congestive 
heart failure, myocardial infarction, and peripheral 
vascular disease. In addition, they had worse metabolic 
profiles, as evidenced by higher homeostasis model 
assessment of insulin resistance (HOMA-IR), higher 
levels of total cholesterol and triglycerides, and lower 
high-density lipoprotein cholesterol (HDL-C) levels. 
However, kidney function did not differ between 
subjects with and those without DM. 
 
Association of DM and CKD with incident muscle 
depletion 
 
During 73,059 person-years of follow-up (median, 
13.7 years; interquartile ranges (IQR), 12.5–14.8 
years), muscle depletion occurred in 460 (7.4%) 
subjects, with a corresponding incidence rate of 6.3 
per 1000 person-years. Table 2 details the event rates 
of muscle depletion, cachexia, and all-cause mortality 
among the four groups. The adjusted cumulative 
incidence of muscle depletion was significantly higher 
in subjects with DM alone and in those with CKD 
alone than in those without the two conditions (Figure 
2A); the incidence in subjects with both DM and CKD 
was the highest. In the cause-specific hazards 
regression model after sequential adjustment for 
confounding factors, the risk of muscle depletion 
development was significantly higher in subjects with 
DM alone than in those without DM and CKD (hazard 
ratio [HR], 1.37; 95% confidence interval [CI], 1.04–
1.80). However, CKD alone was not associated with 
muscle depletion. The HR for muscle depletion was 
notably higher in subjects with the two conditions 
(HR, 3.38; 95% CI, 1.30–8.75) (Table 3). 
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Table 1. Baseline characteristics of patients according to the presence or the absence of diabetes mellitus and 
chronic kidney disease. 
 Non-CKD (N = 5, 996) CKD (N = 251) 
Total (N = 6, 247) 
 
Non-DM  
(N = 5, 161) 
DM (N = 835) 
Non-DM  
(N = 178) 
DM (N = 73) 
Demographic data      
Age (years) 50.4 ± 8.3 54.8 ± 8.8 56.2 ± 9.7 58.3 ± 8.8 51.2 ± 8.6 
Sex (male%) 2, 445 (47.4%) 440 (52.7%) 82 (46.1%) 35 (47.9%) 3, 002 (48.1%) 
BMI (kg/m2) 25.0 ± 2.7 26.0 ± 2.9 25.6 ± 2.8 26.3 ± 3.2 25.2 ± 2.7 
WHR 87.4 ± 7.4 91.5 ± 6.4 90.3 ± 7.4 92.0 ± 6.4 88.1 ± 7.4 
SBP (mmHg) 119.4 ± 17.3 127.2 ± 18.6 127.3 ± 17.9 133.9 ± 17.1 120.8 ± 17.8 
Economic status      
low 1, 506 (29.2%) 326 (39.0%) 71 (39.9%) 28 (38.4%) 1, 931 (30.9%) 
mid 1, 505 (29.2%) 219 (26.2%) 58 (32.6%) 22 (30.1%) 1, 804 (28.9%) 
high 2, 150 (41.7%) 290 (34.7%) 49 (27.5%) 23 (31.5%) 2,512 (40.2%) 
Education status      
low 1, 372 (26.6%) 318 (38.1%) 74 (41.6%) 35 (47.9%) 1, 799 (28.8%) 
mid 2, 994 (58.0%) 399 (47.8%) 76 (42.7%) 33 (45.2%) 3, 502 (56.1%) 
high 795 (15.4%) 118 (14.1%) 28 (15.7%) 5 (6.8%) 946 (15.1%) 
Smoking status      
Never  3, 089 (59.9%) 438 (52.5%) 105 (59.0%) 40 (54.8%) 3, 672 (58.8%) 
Former 851 (16.5%) 172 (20.6%) 36 (20.2%) 19 (26.0%) 1, 078 (17.3%) 
Current 1, 221 (23.7%) 225 (26.9%) 37 (20.8%) 14 (19.2%) 1, 497 (24.0%) 
Alcohol intake      
Never 2, 323 (45.0%) 390 (46.7%) 89 (50.0%) 41 (56.2%) 2, 843 (45.5%) 
Former 297 (5.8%) 61 (7.3%) 13 (7.3%) 6 (8.2%) 377 (6.0%) 
Current 2, 541 (49.2%) 384 (46.0%) 76 (42.7%) 26 (35.6%) 3, 027 (48.5%) 
Insulin user  43 (5.1%)  10 (13.7%) 53 (0.8%) 
Duration of DM      
<5years  655 (78.4%)  50 (68.5%) 705 (77.6%) 
5years to 9 years  89 (10.7%)  8 (11.0%) 97 (10.7%) 
≥10 years  91 (10.9%)  15 (20.5%) 106 (11.7%) 
Comorbidities      
Hypertension 620 (12.0%) 240 (28.7%) 62 (34.8%) 38 (52.1%) 960 (15.4%) 
Coronary artery disease 28 (0.5%) 11 (1.3%) 3 (1.7%) 4 (5.5%) 46 (0.7%) 
Congestive heart failure 7 (0.1%) 5 (0.6%) 0 (0.0%) 0 (0.0%) 12 (0.2%) 
Myocardial infarction 28 (0.5%) 15 (1.8%) 5 (2.8%) 3 (4.1%) 51 (0.8%) 
Peripheral artery 
disease 
11 (0.2%) 5 (0.6%) 2 (1.1%) 1 (1.4%) 19 (0.3%) 
Cerebrovascular disease 41 (0.8%) 16 (1.9%) 9 (5.1%) 1 (1.4%) 67 (1.1%) 
COPD 20 (0.4%) 5 (0.6%) 1 (0.6%) 0 (0.0%) 26 (0.4%) 
Previous cancer history 117 (2.3%) 23 (2.8%) 2 (1.1%) 1 (1.4%) 143 (2.3%) 
Bioimpedance Analysis      
LSM (kg) 44.4 ± 7.9 45.2 ± 8.1 42.6 ± 7.7 43.0 ± 7.1 44.5 ± 8.0 
FFM (kg) 47.0 ± 8.3 47.8 ± 8.5 45.2 ± 8.0 45.6 ± 7.4 47.1 ± 8.3 
FFMI (kg/m2) 18.1 ± 1.6 18.4 ± 1.6 18.0 ± 1.5 18.1 ± 1.4 18.2 ± 1.6 
MET      
Q1 (<25th) 1, 321 (25.6%) 224 (26.8%) 51 (28.7%) 28 (38.4%) 1, 624 (26.0%) 
Q2 (25–49th) 1, 348 (26.1%) 205 (24.6%) 47 (26.4%) 16 (21.9%) 1, 616 (25.9%) 
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Q3 (50–74th) 1, 431 (27.7%) 219 (26.2%) 46 (25.8%) 14 (19.2%) 1, 710 (27.4%) 
Q4 (≥75th) 1, 061 (20.6%) 187 (22.4%) 34 (19.1%) 15 (20.5%) 1, 297 (20.8%) 
Laboratory parameters      
eGFR (mL/min/1.73 m2) 92.5 ± 13.0 89.3 ± 13.1 71.2 ± 22.1 72.7 ± 19.9 91.2 ± 14.1 
≥90 3, 124 (60.5%) 433 (51.9%) 46 (25.8%) 20 (27.4%) 3, 623 (58.0%) 
60–89 2, 037 (39.5%) 402 (48.1%) 32 (18.0%) 18 (24.7%) 2, 489 (39.8%) 
45–59 0 (0.0%) 0 (0.0%) 92 (51.7%) 33 (45.2%) 125 (2.0%) 
<45 0 (0.0%) 0 (0.0%) 8 (4.5%) 2 (2.7%) 10 (0.2%) 
Albuminuria (≥1+) 0 (0.0%) 0 (0.0%) 87 (48.9%) 41 (56.2%) 128 (2.0%) 
BUN (mg/dL) 14.2 ± 3.5 14.8 ± 3.6 17.2 ± 4.9 16.7 ± 4.3 14.4 ± 3.6 
Albumin (g/dL) 4.3 ± 0.3 4.3 ± 0.3 4.2 ± 0.4 4.2 ± 0.4 4.3 ± 0.3 
CRP (mg/dL) 0.1 (0.1-0.2) 0.2 (0.1-0.3) 0.2 (0.1-0.3) 0.3 (0.1-0.5) 0.1 (0.1-0.3) 
Calcium (mg/dL) 9.6 ± 0.5 9.7 ± 0.5 9.6 ± 0.5 9.7 ± 0.6 9.6 ± 0.5 
Fasting glucose (mg/dL) 82.9 ± 8.4 120.8 ± 41.7 84.6 ± 8.8 132.0 ± 47.0 87.9 ± 21.3 
Hemoglobin (g/dL) 13.6 ± 1.6 13.9 ± 1.5 13.6 ± 1.6 13.7 ± 1.9 13.7 ± 1.6 
HbA1c (%) 5.5 ± 0.3 7.2 ± 1.5 5.6 ± 0.3 7.9 ± 2.0 5.8 ± 0.9 
HOMA-IR 1.6 ± 1.0 2.5 ± 1.7 1.6 ± 0.8 3.0 ± 1.9 1.7 ± 1.2 
Tchol (mg/dL) 191.0 ± 34.0 202.2 ± 40.0 206.8 ± 40.6 212.5 ± 46.9 193.2 ± 35.6 












Data are presented as mean ± standard deviation, number (%), or as median and interquartile ranges. Chronic kidney disease 
was defined as eGFR <60 min/min/1.73 m2 or presence of albuminuria at the baseline examination. 
Abbreviations: BMI: body mass index; BUN: blood urea nitrogen; CRP: C-reactive protein; eGFR: estimated glomerular 
filtration rate; FFM: fat free mass; FFMI: fat free mass index; HbA1c: glycated hemoglobin; HDL-C: high density lipoprotein-
cholesterol; LSM: lean soft mass; MET: metabolic equivalent of task; SBP: systolic blood pressure; Tchol: total cholesterol; TG: 





Figure 1. Flow diagram of study cohort. 
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 Non-DM DM Non-DM DM 
No. of participants 6247 5161 835 178 73 
Person-year 73059 61079 9324 1954 701 
Muscle depletion 
Events (%) 460 (7.4) 371 (7.2) 66 (7.9) 17 (9.6) 6 (8.2) 
Events per 1000 person-yr 6. 3 6.1 7.1 8.7 8.6 
Cachexia      
Events (%) 210 (3.4) 170 (3.3) 32 (3.8) 5 (2.8) 3 (4.1) 
Events per 1000 person-yr 2.9 2.8 3.4 2.6 4.3 
All-cause mortality 
Events (%) 203 (3.2) 129 (2.5) 54 (6.5) 11 (6.2) 9 (12.3) 
Events per 1000 person-yr 2.8 2.1 5.8 5.6 12.8 
Abbreviations: DM: diabetes mellitus; CKD: chronic kidney disease. 
 
Table 3. Hazard ratios for muscle depletion development according to diabetes mellitus and chronic kidney disease. 
 Model 1 Model 2 Model 3 
Groups HR [95% CI] P HR [95% CI] P HR [95% CI] P 
Muscle depletion 
Non-DM and Non-CKD 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
DM and Non-CKD 1.40 [1.07–1.84] 0.01 1.42 [1.08–1.86] 0.01 1.37 [1.04–1.80] 0.02 
Non-DM and CKD 1.14 [0.70–1.86] 0.61 1.21 [0.74–1.98] 0.45 1.73 [0.95–3.13] 0.07 
DM and CKD 2.63 [1.17–5.94] 0.02 2.57 [1.14–5.80] 0.02 3.38 [1.30–8.75] 0.01 
Model 1: adjusted for age, sex, body mass index. 
Model 2: adjusted for Model1 plus education status, economic status, alcohol, smoking status, physical activity, 
cardiovascular disease history, previous cancer history, COPD history. 
Model 3: adjusted for Model2 plus systolic blood pressure and laboratory parameters such as estimated glomerular filtration 
rate, proteinuria, HDL-cholesterol, serum calcium, serum albumin, and C-reactive protein. 
Abbreviations: CI: confidence interval; DM: diabetes mellitus; HR: hazard ratio; CKD: chronic kidney disease. 
 
We further examined this association by stratified age 
groups. Not surprisingly, the incidence rate of muscle loss 
was higher in older participants (Supplementary Table 2). 
In addition, the HRs for muscle loss were notably higher 
in participants aged ≥60 years, particularly when they had 
both DM and CKD (Supplementary Table 3). 
 
Association of DM and CKD with the development 
of cachexia and all-cause mortality 
 
The secondary outcome analysis showed results 
consistent with those of the primary outcome analysis 
(Table 2, Supplementary Table 4, and Figure 2B). A 
total of 210 (3.4%) cachexia events were noted during 
the follow-up. Subjects with DM alone were associated 
with a 1.55-fold (95% CI, 1.04–2.30) higher risk of 
cachexia compared to those without DM and CKD, and 
the risk of cachexia was markedly higher in subjects 
with the two conditions (HR, 6.07; 95% CI, 1.50–24.6). 
No significant association between CKD and the risk of 
cachexia was found. 
 
Furthermore, we analyzed the association of DM and 
CKD with the risk of all-cause mortality (Table 2, 
Supplementary Table 4, and Figure 2C). During the 
follow-up, 203 (3.2%) deaths from any cause occurred. 
The risk of all-cause mortality was significantly higher in 
subjects with DM alone than in those without DM and 
CKD (HR, 1.98; 95% CI, 1.43–2.75). The HR in subjects 
with both DM and CKD was 2.62 (95% CI, 1.11–6.19). 
 
Longitudinal changes in fat-free mass, fat mass, and 
body weight 
 
To substantiate our findings further, we compared the 
slopes of changes in fat-free mass, fat mass, lean soft mass, 
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and body weight among the four groups (Figure 3, 
Supplementary Figure 1, and Supplementary Table 5). The 
decline in fat-free mass, FFMI, lean soft mass, and lean 
soft mass index was greater in subjects with DM alone 
than in those without DM and CKD. Similar findings were 
observed in subjects with CKD alone, although the 
magnitude of the decline difference was less than that in 
subjects with DM alone. Moreover, the steepest annual 
decline rates were observed in subjects with both 
conditions. Consistent with these findings, concomitant 
declines in body weight and BMI were noted across the 
four groups. Nonetheless, fat mass declined in subjects 
with DM and CKD and increased in other groups. 
 
Risk of muscle depletion and cachexia with all-cause 
mortality 
 
To examine the prognostic significance of muscle loss, 
we also analyzed whether individuals with muscle 
depletion have a higher risk of mortality. All-cause 
mortality occurred in 23 (5.0%) subjects with muscle 
depletion and in 180 (3.1%) subjects without muscle 
depletion (Supplementary Table 6 and Supplementary 
Figure 2A). In the multivariable Cox regression model 
after adjustment for confounding factors, muscle 
depletion was associated with a 6.42-fold higher risk of 
death (95% CI, 3.87–10.6). This association was greater 
in individuals with cachexia (HR, 10.9; 95% CI, 5.87–
20.1) (Supplementary Table 7 and Supplementary 
Figure 2B). 
 
Glycemic control during follow-up 
 
Lastly, we examined glycemic control among the four 
groups. As expected, time-averaged glycated 
hemoglobin (HbA1c), fasting blood glucose (FBG), and 
2-h postprandial blood glucose (PBG) levels were 
significantly higher in subjects with DM than in those 
without DM. In addition, among the subjects with 
diabetes, glycemic control was similar between those 
without CKD and those with CKD (Supplementary 
Figure 3). These findings suggest that glycemic control 
is unlikely to contribute to the higher muscle depletion 




Figure 2. Cumulative incidence function for development of (A) Incident muscle depletion, (B) Cachexia, and (C) all-cause mortality 
according to diabetes mellitus and chronic kidney disease. 
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DISCUSSION 
 
In this long-term prospective observational cohort 
study, we examined the association of DM and CKD 
with the risk of muscle depletion and cachexia. The 
presence of DM was associated with a significantly 
higher risk of muscle depletion compared to the absence 
of DM and CKD, whereas CKD showed no association 
with muscle loss. Interestingly, the risk of muscle 
depletion was notably higher in those with both DM and 
CKD. Such association was consistent for cachexia 
outcomes and all-cause mortality. Longitudinal tracking 
of body composition also validated these findings. In 
addition, the fastest decline in fat-free mass and BMI 
was observed in subjects with DM and CKD among the 
four groups, and the mortality rate was higher in 
subjects with muscle depletion and cachexia. Our 
findings suggest that DM and CKD can jointly promote 
muscle loss and increase mortality. 
 
Muscle loss is part of the aging process. Muscle mass 
generally starts to decline from the age of 40 years [21]. 
However, excessive muscle loss can occur in patients 
with chronic diseases, such as DM and CKD [8–10]. 
Such loss substantially reduces muscle strength and 
impairs functional capacity, ultimately resulting in 
increased mortality [8, 11, 12]. A number of studies 
have shown that muscle atrophy is highly prevalent in 
patients with DM [8, 10, 22], particularly in the elderly 
and those with diabetic neuropathy [22, 23]. 
Mechanistically, multiple pathways are involved in 
muscle atrophy: insulin resistance, oxidative stress, 
reduced anabolism, inflammatory pathway in the 
muscle via nuclear factor-κB, and increased ubiquitin-
proteasome, lysosomal-proteasome, and caspase 3-
mediated protein degradation [24–26]. Thus, the higher 
risk of muscle depletion and cachexia in subjects with 
DM in our study is not surprising. Our findings are 
consistent with those of previous studies showing that 
muscle mass decreases more rapidly in people with DM 
than in non-diabetic people [10]. Moreover, the tools for 
muscle depletion assessment vary among studies; 
nevertheless, subjects with DM in our cohort showed a 
decline rate of −0.244 kg per year, which is comparable 
to the −0.293 kg per year measured with dual-energy X-




Figure 3. Changes in (A) fat-free mass, (B) fat-free mass index, (C) lean soft mass, and (D) lean soft mass index over time according to 4 
groups by diabetes mellitus and chronic kidney disease. 
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(CT) scan in a previous study [10]. The rate of muscle 
mass decline was 1.4-fold faster in subjects with DM 
than in non-diabetic subjects without CKD. 
 
In addition, subjects with CKD also exhibit muscle 
depletion. Various factors, such as uremic toxin, 
anorexia, and malnutrition, greatly contribute to muscle 
wasting in these patients [27], particularly in those with 
severe kidney failure. In a previous study by Sharma et 
al., the proportion of patients with sarcopenia was 
greater in those with CKD G3 or greater than in those 
with CKD G1-2 [9]. Moreover, muscle wasting is 
exceptionally common in patients with end-stage kidney 
disease receiving dialysis, and these patients with 
muscle wasting have a remarkably high mortality rate 
[28]. However, in our study, CKD alone was not 
associated with muscle depletion. It should be noted 
that subjects with CKD had the mean eGFR of 71.6 
ml/min/1.73 m2 and approximately 96.0% of these 
subjects belonged to CKD G1-G3a. Thus, our cohort 
included few subjects with severe kidney failure. This 
can explain less prominent association between CKD 
and muscle depletion in our study. However, the slope 
of fat-free mass decline was steeper in subjects with 
CKD alone than in those without DM and CKD. 
Moreover, in subjects who had both conditions together, 
the risk of muscle depletion was notably higher than 
those with a single condition alone. These findings can 
be interpreted in two ways. First, although the impact of 
mildly decreased kidney function on muscle depletion 
was not powerful, it can synergically act on the muscle 
wasting process together with DM. Second, subtle loss 
of muscle might not be captured as outcome event. As 
demonstrated in our study, longitudinal assessments of 
body composition appropriately disclosed the gradual 
muscle loss in the long-term in subjects with CKD. 
Hence, careful attention and regular monitoring of 
muscle mass from the early stage of CKD are required 
to prevent muscle wasting. 
 
In our study, subjects with CKD had more preexisting 
cardiovascular diseases and lower income and education 
levels, which are well-known risk factors for incident 
CKD and are also significantly associated with muscle 
wasting. This finding can partly explain the 
exponentially higher risk of muscle depletion and 
cachexia in individuals with DM and CKD. 
 
A decrease in muscle mass is often accompanied by a 
progressive increase in fat mass and subsequent changes 
in body composition [14]. This phenomenon was 
observed in our study. The longitudinal assessment with 
bioimpedance analysis (BIA) showed a decrease in fat-
free mass, which was replaced with fat mass in non-
diabetic subjects without CKD. However, subjects with 
DM without CKD had fat-free mass decline without 
significant changes in fat mass during the follow-up. 
Notably, no compensatory increase in fat mass was 
noted and both fat-free mass and fat mass declined in 
subjects with DM and CKD, resulting in more 
prominent decreases in weight and BMI; this can 
explain the greater incidence of cachexia in these 
subjects. In contrast, previous studies have shown a 
greater loss of fat mass in individuals with DM 
compared with those without DM, particularly among 
elderly individuals [10, 29]. Presumably, our cohort 
characteristics with relatively short duration of DM and 
middle-aged healthy adults may partly explain less 
prominent change in fat mass in subjects with DM 
without CKD. 
 
The strengths of our study include the longitudinal 
design and the detailed examination of muscle mass 
with a long-term follow-up of up to 16 years; detailed 
information on sociodemographic, comorbidity, and 
laboratory data; and rigorous adjustment for 
confounding variables. Based on the BIA results, a 
significant difference in muscle loss among the four 
groups was found. To the best of our knowledge, this 
study is one of the community-based cohort studies with 
the longest follow-up. 
 
Nevertheless, this study has several limitations. First, 
owing to the observational study design, we could not 
draw any conclusions about the causal effect of DM and 
CKD on muscle depletion or cachexia. Moreover, 
whether weight loss occurred unintentionally or not is 
unknown. Interestingly, there were few individuals with 
extreme obesity and the KoGES cohort had few chronic 
debilitating diseases. Although these characteristics 
suggest that intended weight loss was unlikely, the 
KoGES database did not include detailed information 
on this issue. Second, the KoGES did not perform 
functional assessments, including muscle strength and 
physical performance. There is ample evidence that 
such measures predict clinically relevant adverse events 
in older people [30]. Moreover, a functional assessment 
of muscle performance would be more helpful in 
delineating the clinical implication of quantitative loss 
of muscle mass. Third, we used BIA only for the 
assessment of body composition. Fat-free mass includes 
body water, bone, organs, and muscle content; thus, 
BIA may not be the best method to accurately assess 
muscle mass. There are other tools that can reliably 
determine body composition, such as DEXA, CT scan, 
or magnetic resonance imaging scan [31, 32]. However, 
the multifrequency BIA system is a safe and cost-
effective method that can provide accurate muscle and 
fat mass contents; thus, it is easily implemented in 
clinical practice. Previous studies also reported that the 
accuracy between BIA and DEXA is comparable [33]. 
Forth, the subjects in this community-based cohort were 
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relatively healthy with few comorbidities, and only 
4.02% of the subjects had eGFR <60 mL/min/1.73 m2 
or albuminuria. Thus, we were not able to evaluate the 
association of CKD with muscle depletion across a wide 
range of eGFRs. Fifth, despite few comorbidities, 
heterogeneity of our cohort may challenge the external 
validity of the findings. Unfortunately, there is no 
available cohort dataset having BIA and longitudinal 
follow-up assessments of various parameters in Korea. 
Lastly, we included only Korean individuals aged 40 to 
69 years; thus, further studies including other ethnic 
groups or more elderly individuals are needed. 
 
In conclusion, in this long-term prospective community-
based cohort study including middle-aged Korean 
adults, those with DM were more likely to experience 
muscle depletion and cachexia. Muscle mass loss and 
weight loss were more pronounced in those with both 
DM and CKD, ultimately leading to a higher mortality 
risk. Our findings provide insight into public healthcare, 
highlighting the importance of early preventative 
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All subjects voluntarily participated in this study and 
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Korean National Institute of Health. This study was 
performed in accordance with the Declaration of 
Helsinki and approved by the institutional review board 





We used data from the KoGES, which is a prospective 
community-based cohort study. The details of the 
rationale, design, methods, and protocol summary were 
previously described [34]. Briefly, the study cohort 
consisted of participants recruited from the national 
health examinee registry, 10,030 subjects aged 40–69 
years with a homogeneous ethnic background who were 
residents of Ansan (urban area) and Ansung (rural area), 
which are located near the capital city of Seoul, South 
Korea. For baseline recruitment, eligible participants 
were asked to volunteer through on-site invitations, 
telephone calls, mailed letters, community leader-
mediated conferences, or media campaigns. The 
subjects underwent anthropometric examinations and 
laboratory tests and completed health-related lifestyle 
questionnaires in 2001 (baseline), and the tests were 
repeated biennially until 2016. The subject retention 
rate was 70.6% at the end of the seventh follow-up 
phase (16 years of follow-up). Key exclusion criteria 
were as follows: 1) subjects who did not undergo BIA at 
baseline (n = 2191); 2) those with muscle depletion at 
baseline (n = 813), and those with a BMI <20 kg/m2 (n 
= 107). We excluded subjects with other missing data 
and those who were lost to follow-up after the baseline 
visit. Thus, a total of 6247 subjects were included in the 
final analysis (Figure 1). 
 
Demographic, anthropometric, and laboratory data 
 
Demographic and socioeconomic data, including age, 
sex, education and income levels, smoking status, 
alcohol intake, and medical histories, were obtained at 
study entry. Anthropometric parameters, such as height 
and weight, were measured by trained researchers 
according to a specified protocol: height was measured 
to the nearest 0.1 cm using a stadiometer with the 
subjects standing barefoot, weight was measured with 
the subjects wearing light clothes and no shoes, and 
BMI was calculated by dividing weight (kg) by height 
squared (m2). Moreover, based on surveys with a 
semiquantitative questionnaire, physical activity level 
was calculated as the daily estimated metabolic 
equivalents of task (MET) and was divided into 
quartiles. One MET is approximately 3.5 mL of oxygen 
consumed per kilogram of body weight per minute at 
rest. To obtain MET, subjects reported hours spent on 
sleep and five types of activities that were categorized 
according to intensity of activity: sedentary, very light, 
light, moderate, and heavy. Total MET hours per day 
were calculated by multiplying the reported hours spent 
by the MET that were determined based on each 
activity type [35]. In addition, education level was 
classified into three groups according to education 
duration: ≤6 years, 6–9 years, and >9 years. Income 
level was divided into three groups based on the 
average per-person monthly income: <$850, $850–
$1699, and ≥$1700 per month. 
 
Blood samples were obtained after an 8-h fast, 
transported to Seoul Clinical Laboratories (Seoul, 
Republic of Korea) within 24 h of sampling, and 
analyzed for the following biochemical parameters: 
serum creatinine, blood urea nitrogen, glucose, HbA1c, 
calcium, albumin, total cholesterol, triglyceride, HDL-
C, and C-reactive protein (CRP). Serum creatinine was 
measured using the Jaffe method during the follow-up 
period; thus, we converted the non-isotope dilution-
mass spectrometry (IDMS) creatinine to IDMS 
creatinine using the equation that was previously 
suggested [36, 37]. Subsequently, eGFR was calculated 
using the CKD Epidemiology Collaboration equation 
[38]. To evaluate insulin resistance, HOMA-IR was 
calculated using fasting glucose and insulin levels [39]. 
Urine samples were collected in the morning after the 
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first voiding, and dipstick test was performed using 
URISCAN Pro II (YD Diagnostics Corp., Seoul, 
Korea). Urine albumin was quantified as absent, trace, 
1+, 2+, or 3+ based on a color scale. Albuminuria was 
defined as albumin level ≥1+ based on the dipstick test. 
 
Assessment of body composition 
 
Body composition was assessed using multifrequency 
BIA (InBody 3.0, Biospace, Seoul, Korea). BIA was 
performed at baseline and biennially during the entire 
study period. Compared with conventional BIA-based 
methods that rely on formulae to calculate the estimated 
mass of each body component, multifrequency BIA 
assumes that the human body consists of five 
interconnecting cylinders and performs impedance 
measurements directly on these compartments. 
Impedances were measured at four specific frequencies 
(5, 50, 250, and 500 kHz) in five segments (both arms, 
trunk, and both legs) using a tetrapolar 8-point tactile 
electrode system. 
 
Definition of diabetes mellitus and chronic kidney 
disease 
 
DM was defined as DM diagnosis before study 
enrollment or receiving antidiabetic medications or 
insulin. Newly diagnosed DM was defined based on the 
American Diabetes Association criteria: FBG level 
≥126 mg/dL (7.0 mmol/L), PBG ≥200 mg/dL (11.1 
mmol/L) after 75-g oral glucose tolerance test, or 
HbA1c ≥6.5% (48 mmol/mol) [40]. Serum 
concentrations of HbA1c, FBG, and PBG were 
measured in all subjects at each follow-up visit. 
 
CKD was defined as eGFR <60 mL/min/1.73 m2 or 
presence of albuminuria at baseline examination 
according to the Kidney Disease Improving Global 
Outcomes guidelines [41]. 
 
Exposure and outcome 
 
The main exposures of interest were DM and CKD. 
Patients were classified into four groups according to 
the presence or absence of the two diseases as follows: 
1) without DM and CKD, 2) DM without CKD, 3) CKD 
without DM, and 4) with both DM and CKD. The 
primary endpoint was de novo development of muscle 
depletion, which was defined as a decline in FFMI 
based on BIA below the 10th percentile of the total 
KoGES population sample (male <16.9 kg/m2 and 
female <15.2 kg/m2). 
 
The secondary outcomes included the development of 
incident cachexia, all-cause mortality, and the slopes of 
changes in fat-free mass, fat mass, and body weight 
during the follow-up. Cachexia is an extreme type of 
muscle loss; thus, it was defined as muscle depletion 
with BMI <20 kg/m2 or a decrease in body weight 
≥10% for 24 months [14]. Primary outcome events 
were determined based on two or more event 
measurements, and the first of which was designated as 




Data were analyzed using STATA version 15 software 
(StataCorp, College Station, TX, USA). Continuous 
variables were expressed as means ± standard 
deviations; categorical variables, as absolute numbers 
with percentages. All data were tested for normality 
before the statistical analysis. The Kolmogorov–
Smirnov test was performed to determine the normality 
of the parameter distribution. Intergroup comparisons 
were conducted using analysis of variance for normally 
distributed continuous variables and the χ2 test or 
Fisher’s exact test for categorical variables. Data that 
did not show a normal distribution were presented as 
medians with IQR and compared using the Mann–
Whitney U test or Kruskal–Wallis test. Cumulative 
incidence curves for individual muscle depletion and 
cachexia outcomes were derived using cumulative 
incidence functions considering competing risks. The 
Gray test was employed to determine statistically 
significant differences among groups. 
 
Moreover, survival time was defined as the time 
interval between the baseline and the onset of the 
outcome or the last follow-up. Multivariable cause-
specific hazards regression models were constructed to 
determine the association of DM and CKD with the 
risk of incident muscle depletion and cachexia. 
Variables that presented statistical significance in the 
univariable analysis were included in the multivariable 
models. Model 1 was adjusted for baseline age, sex, 
and BMI. Model 2 included demographic factors 
(education, income, alcohol consumption, smoking, 
and MET) and the presence of comorbidities, such as 
cardiovascular disease (myocardial infarction, 
congestive heart failure, unstable angina, peripheral 
artery disease, and cerebrovascular disease), previous 
cancer, and chronic obstructive pulmonary disease. 
Model 3 was further adjusted for SBP, eGFR, 
albuminuria, HDL-cholesterol, serum calcium, serum 
albumin, and CRP. Deaths before the occurrence of the 
primary outcome were treated as a competing risk and 
censored. Patients who were lost to follow-up were 
censored at the date of the last examination. We also 
compared the slopes of changes in fat-free mass, fat 
mass, lean soft mass, body weight, BMI, and adjusted 
with height index among the four groups using a 
generalized linear mixed model that incorporated 
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random slopes and random coefficients. P values <0.05 
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Supplementary Figure 1. Changes in (A) Fat mass, (B) Fat mass index, (C) Body weight, and (D) BMI over time according to 4 groups by 
diabetes mellitus and chronic kidney disease. 
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Supplementary Figure 2. Cumulative incidence function for development of all-cause mortality according to (A) incident muscle 
depletion and (B) cachexia. 
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Supplementary Figure 3. Glycemic control during follow-up: (A) HbA1c; (B) fasting glucose; and (C) 2-h postprandial blood glucose. 
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Supplementary Tables 
 




















Age <0.01 <0.01 0.29 <0.01 <0.01 0.38 
Sex <0.01 0.73 0.92 0.11 0.44 0.79 
BMI <0.01 0.03 0.47 <0.01 1.00 0.04 
WHR <0.01 <0.01 0.33 <0.01 1.00 0.54 
SBP <0.01 <0.01 1.00 <0.01 0.01 0.04 
Economic status <0.01 <0.01 0.14 0.11 0.74 0.81 
Education status <0.01 <0.01 <0.01 0.47 0.11 0.16 
Smoking status <0.01 0.36 0.09 0.19 0.28 0.60 
Alcohol intake 0.09 0.21 0.07 0.71 0.23 0.58 
Insulin user <0.01 N/A <0.01 <0.01 <0.01 <0.01 
Duration of DM N/A N/A N/A N/A 0.10 N/A 
Hypertension <0.01 <0.01 <0.01 0.11 <0.01 0.01 
Coronary artery disease 0.01 0.05 <0.01 0.70 <0.01 0.04 
Congestive heart failure <0.01 0.62 0.75 0.30 0.51 N/A 
Myocardial infarction <0.01 <0.01 <0.01 0.38 0.17 0.59 
Peripheral artery disease 0.04 0.02 0.04 0.44 0.44 0.87 
Cerebrovascular disease <0.01 <0.01 0.58 0.01 0.74 0.18 
COPD 0.38 0.72 0.59 0.95 0.51 0.52 
Previous cancer history 0.39 0.31 0.61 0.20 0.48 0.87 
LSM 0.06 1.00 0.11 1.00 1.00 1.00 
FFM 0.06 1.00 0.11 1.00 1.00 1.00 
FFMI <0.01 1.00 0.08 1.00 1.00 1.00 
MET 0.41 0.79 0.07 0.77 0.19 0.39 
eGFR 0.06 0.04 0.01 0.01 0.01 0.07 
Albuminuria N/A <0.01 <0.01 <0.01 <0.01 0.29 
BUN <0.01 <0.01 <0.01 <0.01 <0.01 1.00 
Albumin 0.65 1.00 0.83 1.00 1.00 1.00 
CRP <0.01 0.05 1.00 <0.01 <0.01 0.05 
Calcium <0.01 1.00 0.87 1.00 1.00 1.00 
Fasting glucose <0.01 1.00 <0.01 <0.01 <0.01 <0.01 
Hemoglobin <0.01 1.00 0.05 1.00 1.00 1.00 
HbA1c <0.01 0.42 <0.01 <0.01 <0.01 <0.01 
HOMA-IR <0.01 1.00 <0.01 <0.01 <0.01 <0.01 
Tchol <0.01 <0.01 0.69 <0.01 0.10 0.04 
HDL-C <0.01 1.00 0.43 0.07 1.00 1.00 
TG <0.01 <0.01 1.00 <0.01 1.00 0.03 
Abbreviations: BMI: body mass index; BUN: blood urea nitrogen; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; FFM: 
fat free mass; FFMI: fat free mass index; HbA1c: glycated hemoglobin; HDL-C: high density lipoprotein-cholesterol; SBP: systolic blood 
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Supplementary Table 2. Event rates of muscle depletion among groups classified by diabetes mellitus and chronic 
kidney disease stratified by age. 
 Total 
Non-CKD CKD 
Non-DM DM Non-DM DM 
No. of participants 6247 5161 835 178 73 
Person-year 73059 61079 9324 1954 701 
Muscle depletion      
40~59 years      
No. of participants 4868 4197 541 94 36 
Events (%) 292 (6.0) 246 (5.9) 36 (6.7) 8 (8.5) 2 (5.6) 
Events per 1000 person-yr 5.2 5.0 5.8 7.6 5.0 
60~69 years      
No. of participants 1379 964 294 84 37 
Events (%) 168 (12.2) 125 (13.0) 30 (10.2) 9 (10.7) 4 (10.8) 
Events per 1000 person-yr 12.1 12.6 10.4 10.6 14.1 
Abbreviations: DM: diabetes mellitus; CKD: chronic kidney disease. 
 
 
Supplementary Table 3. Hazard ratios for muscle depletion development according to diabetes mellitus and chronic 
kidney disease stratified by age. 
Age groups 
Model 1 Model 2 Model 3 
HR [95% CI] P HR [95% CI] P HR [95% CI] P 
40~59 years       
Non-DM and Non-CKD 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
DM and Non-CKD 1.88 [1.32–2.69] <0.01 1.94 [1.36–2.79] <0.01 1.85 [1.28–2.66] <0.01 
Non-DM and CKD 1.86 [0.92–3.76] 0.09 1.92 [0.95–3.90] 0.07 3.09 [1.19–8.05] 0.02 
DM and CKD 1.85 [0.46–7.53] 0.39 1.83 [0.45–7.46] 0.40 2.35 [0.49–11.2] 0.28 
60~69 years       
Non-DM and Non-CKD 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
DM and Non-CKD 1.02 [0.68–1.52] 0.94 1.04 [0.69–1.57] 0.84 1.07 [0.70–1.62] 0.76 
Non-DM and CKD 0.86 [0.43–1.70] 0.66 0.93 [0.47–1.84] 0.83 1.24 [0.51–3.02] 0.64 
DM and CKD 3.17 [1.14–8.79] 0.03 3.14 [1.12–8.82] 0.03 4.54 [1.33–15.5] 0.02 
Model 1: adjusted for age, sex, body mass index. 
Model 2: adjusted for Model1 plus education status, economic status, alcohol, smoking status, physical activity, 
cardiovascular disease history, previous cancer history, COPD history. 
Model 3: adjusted for Model2 plus systolic blood pressure and laboratory parameters such as estimated glomerular filtration 
rate, proteinuria, HDL-cholesterol, serum calcium, serum albumin, and C-reactive protein. 
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Supplementary Table 4. Hazard ratios for cachexia and all-cause death development according to diabetes mellitus 
and chronic kidney disease. 
Groups 
Model 1 Model 2 Model 3 
HR [95% CI] P HR [95% CI] P HR [95% CI] P 
Cachexia       
Non-DM and Non-CKD 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
DM and Non-CKD 1.56 [1.06–2.30] 0.02 1.59 [1.08–2.34] 0.02 1.55 [1.04–2.30] 0.03 
Non-DM and CKD 0.78 [0.32–1.92] 0.59 0.87 [0.35–2.14] 0.76 1.27 [0.47–3.48] 0.64 
DM and CKD 3.06 [0.96–9.70] 0.06 3.05 [0.96–9.73] 0.06 6.07 [1.50–24.6] 0.01 
All-cause death       
Non-DM and Non-CKD 1.00 [Reference]  1.00 [Reference]  1.00 [Reference]  
DM and Non-CKD 1.92 [1.38–2.65] <0.01 1.93 [1.39–2.67] <0.01 1.98 [1.43–2.75] <0.01 
Non-DM and CKD 1.82 [0.98–3.38] 0.06 1.80 [0.97–3.36] 0.06 1.29 [0.57–2.92] 0.54 
DM and CKD 3.46 [1.74–6.90] <0.01 3.30 [1.65–6.60] <0.01 2.62 [1.11–6.19] 0.03 
Model 1: adjusted for age, sex, body mass index. 
Model 2: adjusted for Model1 plus education status, economic status, alcohol, smoking status, physical activity, 
cardiovascular disease history, previous cancer history, COPD history. 
Model 3: adjusted for Model2 plus systolic blood pressure and laboratory parameters such as estimated glomerular filtration 
rate, proteinuria, HDL-cholesterol, serum calcium, serum albumin, and C-reactive protein. 
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Supplementary Table 5. Rates of decline in fat-free mass, fat-free mass index, lean soft mass, lean soft mass index, 
fat mass, fat mass index, body weight and BMI according to diabetes mellitus and chronic kidney disease. 
 Slope of FFM (kg/year, 95% CI) P Slope of FFMI (kg/m2/year, 95% CI) P 
Non-DM and Non-CKD −0.1727 (−0.1763 to −0.1691)  −0.0568 (−0.0582 to −0.0555)  
DM and Non-CKD −0.2442 (−0.2537 to −0.2348) <0.001 −0.0826 (−0.0861 to −0.0790) <0.001 
Non-DM and CKD −0.2052 (−0.2260 to −0.1845) <0.001 −0.0677 (−0.0755 to −0.0599) 0.007 
DM and CKD −0.2628 (−0.2988 to −0.2268) <0.001 −0.0931 (−0.1066 to −0.0796) <0.001 
 Slope of LSM (kg/year, 95% CI)  Slope of LSMI (kg/m2/year, 95% CI)  
Non-DM and Non-CKD −0.1610 (−0.1644 to −0.1576)  −0.0527 (−0.0540 to −0.0514)  
DM and Non-CKD −0.2308 (−0.2397 to −0.2220) <0.001 −0.0779 (−0.0812 to −0.0746) <0.001 
Non-DM and CKD −0.1925 (−0.2120 to −0.1731) 0.002 −0.0633 (−0.0706 to −0.0561) 0.005 
DM and CKD −0.2490 (−0.2827 to −0.2152) <0.001 −0.0882 (−0.1007 to −0.0756) <0.001 
 Slope of FM (kg/year, 95% CI)  Slope of FMI (kg/m2/year, 95% CI)  
Non-DM and Non-CKD 0.1364 (0.1312 to 0.1415)  0.0578 (0.0558 to 0.0599)  
DM and Non-CKD 0.0139 (0.0005 to 0.0273) <0.001 0.0099 (0.0046 to 0.0152) <0.001 
Non-DM and CKD 0.1042 (0.0747 to 0.1336) 0.035 0.0479 (0.0362 to 0.0597) 0.103 
DM and CKD −0.0424 (−0.0934 to 0.0087) <0.001 −0.0107 (−0.0310 to 0.0096) <0.001 
 Slope of Weight (kg/year, 95% CI)  Slope of BMI (kg/m2/year, 95% CI)  
Non-DM and Non-CKD −0.0482 (−0.0541 to −0.0423)  −0.0031 (−0.0054 to −0.0008)  
DM and Non-CKD −0.2521 (−0.2674 to −0.2368) <0.001 −0.0799 (−0.0858 to −0.0739) <0.001 
Non-DM and CKD −0.1154 (−0.1490 to −0.0818) <0.001 −0.0264 (−0.0395 to −0.0134) <0.001 
DM and CKD −0.2824 (−0.3405 to −0.2243) <0.001 −0.0923 (−0.1149 to −0.0697) <0.001 
Abbreviations: BMI: body mass index; CI: confidence interval; CKD: chronic kidney disease; DM: diabetes mellitus; FM: fat mass; FMI: fat 
mass index; FFM: fat free mass; FFMI: fat free mass index; HR: hazard ratio; LSM: lean soft mass; LSMI: lean soft mass index. 
 
 
Supplementary Table 6. Hazard ratios for all-cause death in individuals with muscle depletion. 
 Total Non-muscle depletion Muscle depletion 
No. of participants Person-year 
All-cause mortality 
Events (%) 
Events per 1000 person-year 
Cox proportional hazards model 
6247  5787   460  
70102  67590   2512  
203 (3.2)  180 (3.1)   23 (5.0)  
2.9  2.7   9.2  
 HR [95% CI] p HR [95% CI] p 
Model 1  1.00 [Reference]  6.39 [3.88–10.5] <0.01 
Model 2  1.00 [Reference]  6.41 [3.88–10.6] <0.01 
Model 3  1.00 [Reference]  6.42 [3.87–10.6] <0.01 
Model 1: adjusted for age, sex, body mass index. 
Model 2: adjusted for Model1 plus education status, economic status, alcohol, smoking status, physical activity, cardiovascular disease 
history, previous cancer history, COPD history. 
Model 3: adjusted for Model2 plus systolic blood pressure and laboratory parameters such as estimated glomerular filtration rate, 




www.aging-us.com 21961 AGING 
Supplementary Table 7. Hazard ratios for all-cause death in individuals with cachexia. 
 Total Non-cachexia Cachexia 
No. of participants Person-year 
All-cause mortality 
Events (%) 
Events per 1000 person-year 
6247  6037   210  
71957  71003   954  
203 (3.2)  189 (3.1)   14 (6.7)  
2.8  2.7   14.7  
Cox proportional hazards model  HR [95% CI] p HR [95% CI] p 
Model 1  1.00 [Reference]  10.3 [5.61–18.8] <0.01 
Model 2  1.00 [Reference]  10.2 [5.53–18.6] <0.01 
Model 3  1.00 [Reference]  10.9 [5.87–20.1] <0.01 
Model 1: adjusted for age, sex, body mass index. 
Model 2: adjusted for Model1 plus education status, economic status, alcohol, smoking status, physical activity, cardiovascular disease 
history, previous cancer history, COPD history. 
Model 3: adjusted for Model2 plus systolic blood pressure and laboratory parameters such as estimated glomerular filtration rate, 
proteinuria, HDL-cholesterol, serum calcium, serum albumin, and C-reactive protein. 
 
 
 
